Barclays analyst Gena Wang lowered the firm’s price target on Legend Biotech (LEGN) to $90 from $94 and keeps an Overweight rating on the shares following the Q3 report.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech’s Q3 2025: Strong CARVYKTI® Sales
- Legend Biotech’s Earnings Call Highlights Growth and Challenges
- Strong Buy Recommendation for Legend Biotech Driven by Market Position and Growth Potential
- Legend Biotech’s Strategic Growth and Risks: Analyst Assigns Hold Rating
- Legend Biotech Reports Strong Q3 2025 Results and CARVYKTI® Progress